A drug (INS018_055) for idiopathic pulmonary fibrosis

You may qualify if

• Male or female patients aged ≥40 years based on the date of the written informed consent form
• Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines
• In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation
• Meeting all of the following criteria during the screening period:; FVC ≥40% predicted normal; DLCO corrected for Hgb ≥25% and <80% predicted normal; Forced Expiratory Volume in the first second/FVC (FEV1/FVC) ratio >0.7 based on pre-bronchodilator value

You can't join if

• Acute IPF exacerbation within 4 months prior to Visit 1 and/or Day 1, as determined by the investigator
• Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study
• Female patients who are pregnant or nursing
• Abnormal ECG findings